Dexcom (DXCM) lagged the most bullish expectations for its adjusted first-quarter earnings, but offered an otherwise broad beat. Still, Dexcom stock skidded Friday.
XOn average, analysts polled by FactSet expected the diabetes devices giant to earn 15 cents a share, excluding some items. Dexcom's profit beat that at 17 cents per share, though it missed the most bullish projections at 20 cents a share.
Sales climbed 18% to $741.5 million and easily topped forecasts for $720.7 million.
But in premarket trading on today's stock market, Dexcom stock tumbled 3.8% near 118.90. Shares are consolidating with a buy point at 125.65, according to MarketSmith.com.
Dexcom Stock: Sales Growth Slows
Dexcom has posted quarterly sales growth of 17% to 19% for four straight quarters now. But that has slowed from earlier growth of 25%-31%. The slowdown could make Dexcom stock investors nervous.
But the company says it's still early in the continuous glucose monitor, or CGM, business. CGMs are body-worn devices that monitor a user's blood sugar in real time. They can be paired with insulin pumps to help ease the management of diabetes.
CGMs have historically been used primarily in the type 1 diabetes market. In this genetic form of the disease, patients' bodies don't make their own insulin. So patients are reliant on insulin pumps or multiple daily injections. Type 2 diabetes is a progressive condition.
Now, the Centers for Medicare and Medicaid Services is covering a broader group of patients with the progressive condition. The decision on March 2 pushed Dexcom stock 9.5% higher.
Full-Year Guidance Raised
Dexcom also recently launched a new CGM dubbed G7 in the U.S.
In response to the strong demand and new CGM coverage, Dexcom raised its full-year outlook. Now the company expects $3.4 billion to $3.52 billion in sales. Dexcom stock analysts were projecting $1.06 in earnings per share and $3.47 billion in sales.
Three months ago, Dexcom forecast $3.35 billion to $3.49 billion in sales.
Dexcom stock has a nearly perfect IBD Digital Composite Rating of 98. This means shares rank in the leading 2% of all stocks in terms of fundamental and technical metrics.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Eli Lilly Unveils New Obesity Data As Mounjaro Blows Past Sales Estimates
AbbVie's Humira Downfall Is Swift As Biosimilars Hammer Away At Sales
See Stocks On The List Of Leaders Near A Buy Point
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
